Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Cancer Res. 2014 Oct 21;74(24):7260–7273. doi: 10.1158/0008-5472.CAN-14-0876

Figure 3. CCR2-deficient mice have an initial increase in viral infection but are cleared of virus with similar kinetics as the wildtype animals.

Figure 3

Wildtype or CCR2-/- C57Bl/6 mice implanted with K1492 cells were treated at 14 dpi with 5.0×106 PFUs of vMyxv-FLuc or left untreated. A – Measurement of viral bioluminescence. Error bars represent standard error and asterisks represent significant difference at given time point (n=9/group; p>0.05). B – Viral recovery assay from wildtype (WT) or CCR2-deficient (CCR2) mice bearing 14 day K1492 tumours and infected with 1.5×107 PFU vMyx-FLuc 3 days post-treatment. Error bars represent standard error and asterisk represents significant difference (n=3/group; p<0.05). C – Immunohistochemical staining with H&E or viral protein M-T7 of CCR2-defcient K1492-bearing animals 3 days post-infection with 5×106 FFUs of MYXV. Representative image of 3 animals. D - Kaplan-Meier survival curve of K1492-bearing wildtype (WT) or CCR2-deficeint(CCR2) C57Bl/6 mice treated with 5.0×106 PFUs of vMyxv-FLuc (MYXV). n=9/group.